COMP <GO>
GILD vs LLY // RSI-14 & 200D SMA MOMENTUM
Gilead Sciences Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GILD 6
— LLY 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
rsi-technicals
74.3
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 83.64% | -4.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 32.36% | -11.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 36.4x | -15.42 | GILD | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 2.30% | +2.30 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | 40.21% | -6.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 31.90% | -3.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 45.51% | -43.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 0.49% | +1.46 | GILD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 9.29 | -3.42 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | GILD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 74.3 | 77.9 | -3.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.51 | +0.37 | GILD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 26.3x | -3.85 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $1.33T | -$1.13T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | LLY REV | GILD GROSS % | LLY GROSS % | GILD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $65.18B | 78.8% | 83.0% | $9.46B | $16.81B |
| FY 2024 | $28.75B | $45.04B | 78.3% | 81.3% | $10.30B | $8.82B |
| FY 2023 | $27.12B | $34.12B | 44.0% | 79.3% | $6.79B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
LLY // BETA 0.51